Monopar Therapeutics Inc. Unrecognized Tax Benefits, Period Increase (Decrease)
Monopar Therapeutics Inc. (MNPR) reported Unrecognized Tax Benefits, Period Increase (Decrease) of $222.46 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease · last filed 2026-03-27
- Monopar Therapeutics Inc. unrecognized tax benefits, period increase (decrease) for fiscal 2025 was $222.46K, a 240.21% increase from fiscal 2024.
- Monopar Therapeutics Inc. unrecognized tax benefits, period increase (decrease) for fiscal 2024 was $65.39K, a 0.00% change from fiscal 2023.
- Monopar Therapeutics Inc. unrecognized tax benefits, period increase (decrease) for fiscal 2023 was $65.39K, a 56.61% decline from fiscal 2022.
- Monopar Therapeutics Inc. unrecognized tax benefits, period increase (decrease) for fiscal 2022 was $150.70K, a 226.96% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Period Increase (Decrease) 12 month |
|---|---|
| 2025-12-31 | $222.46K 10-K · filed 2026-03-27 |
| 2024-12-31 | $65.39K 10-K · filed 2026-03-27 |
| 2023-12-31 | $65.39K 10-K · filed 2025-03-31 |
| 2022-12-31 | $150.70K 10-K · filed 2024-03-28 |
| 2021-12-31 | $46.09K 10-K · filed 2023-03-23 |
| 2020-12-31 | $44.79K 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |